Loading
Latest filing published 11 Sept 2023 for NRX Pharmaceuticals, Inc., €10k. Read the official filing
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Aaron Gorovitz, listed as board member, appears in our data through filings on NRX Pharmaceuticals, Inc. shares, published by SEC (Form 4). We count 2 filings; the first trade dates from 24 May 2021 and the latest from 30 August 2023.
Every open-market trade on record is a purchase: 1 purchase worth €10k, and no sale. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Outside the open market, there are 1 share grant. Since January 2023: 1 purchase and no sales on the market.
The record was last updated on 11 September 2023 with an open-market purchase (€10k) in NRX Pharmaceuticals, Inc. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
2 of 2 declarations